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Abstract
Summary The Women's Health Initiative (WHI) double-
blind, placebo-controlled clinical trial randomly assigned
36,282 postmenopausal women in the U.S. to 1,000 mg ele-
mental calcium carbonate plus 400 IU of vitamin D3 daily or
placebo, with average intervention period of 7.0 years. The
trial was designed to test whether calcium plus vitamin D
supplementation in a population in which the use of these
supplements was widespread would reduce hip fracture, and
secondarily, total fracture and colorectal cancer.
Introduction This study further examines the health benefits
and risks of calcium and vitamin D supplementation using
WHI data, with emphasis on fractures, cardiovascular dis-
ease, cancer, and total mortality.
Methods WHI calcium and vitamin D randomized clinical
trial (CT) data through the end of the intervention period
were further analyzed with emphasis on treatment effects in
relation to duration of supplementation, and these data were
contrasted and combined with corresponding data from the
WHI prospective observational study (OS).
Results Among women not taking personal calcium or vi-
tamin D supplements at baseline, the hazard ratio [HR] for
hip fracture occurrence in the CT following 5 or more years
of calcium and vitamin D supplementation versus placebo
was 0.62 (95 % confidence interval (CI), 0.38–1.00). In
combined analyses of CT and OS data, the corresponding
HR was 0.65 (95 % CI, 0.44–0.98). Supplementation effects
were not apparent on the risks of myocardial infarction,
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coronary heart disease, total heart disease, stroke, overall
cardiovascular disease, colorectal cancer, or total mortality,
while evidence for a reduction in breast cancer risk and total
invasive cancer risk among calcium plus vitamin D users
was only suggestive.
Conclusion Though based primarily on a subset analysis,
long-term use of calcium and vitamin D appears to confer a
reduction that may be substantial in the risk of hip fracture
among postmenopausal women. Other health benefits and
risks of supplementation at doses considered, including an
elevation in urinary tract stone formation, appear to be
modest and approximately balanced.
Keywords Calcium . Cancer . Cardiovascular disease .
Fractures . Health risks and benefits . Vitamin D
Introduction
The Women's Health Initiative (WHI) double-blind, placebo-
controlled clinical trial (CT) randomly assigned 36,282
postmenopausal women in the U.S. to 1,000 mg elemental
calcium carbonate plus 400 IU of vitamin D3 daily or
placebo, with average intervention period of 7.0 years.
The trial was designed to test whether calcium plus vitamin
D (CaD) supplementation in a population in which the use of
these supplements was widespread would reduce hip fracture,
and secondarily, total fracture and colorectal cancer. Even
though CaD led to a significantly higher hip and total body
bone mineral density than placebo (P<0.01), there was no
compelling evidence for hip or total fracture risk reduction
[1]. Among women who adhered to study medications, how-
ever, there was a lower hip fracture incidence in the interven-
tion group [1], though this type of adherence-adjusted analysis
involves additional modeling assumptions and lacks the reli-
ability of the corresponding intention-to-treat analysis. Addi-
tional analyses led to reports of no clear evidence of benefit or
harm for colorectal cancer [2], breast cancer [3], or other
invasive cancer [4], though the possibility of a breast cancer
risk reduction among women using little or no personal calci-
um supplements was noted [3]. Additional reports noted no
clear evidence of influence on coronary heart disease (CHD)
risk, defined inWHI and here as nonfatalmyocardial infarction
(MI) or CHD death [5], and to the possibility of a reduction in
total mortality [6]. A modest elevation in urinary tract stone
occurrence in the intervention group was also observed [1, 7].
The WHI trial has been criticized in that participating
women were allowed to continue their personal use of calcium
and/or vitamin D, in addition to taking study pills [8]. Our
perspective, as WHI investigators, is that the question of
health risks and benefits associated with CaD supplementa-
tion, beyond the use of personal supplements, is of direct
importance to postmenopausal women in the general
population. We agree, however, that subset analyses restricted
to women not taking personal supplements are of considerable
interest from both etiologic and public health perspectives.
Bolland et al. [8] reanalyzed WHI CaD trial data and
reported an interaction (P=0.04) in hazard ratio (HR) for
“clinical MI” according to whether or not women were not
using personal calcium supplements at baseline. A similar
interaction was reported for combined clinical MI and
stroke. These authors summarize that WHI trial data do
not provide “definitive evidence” of an adverse effect of
calcium and vitamin D on cardiovascular events, but they
argue that data from other trials of calcium and vitamin D, or
of calcium alone, in conjunction with WHI data, lead to the
conclusion that calcium supplements with or without vita-
min D increase the risk of cardiovascular events.
Essentially the same investigator group reanalyzed the
WHI trial data further and reported [9] an HR interaction for
total cancer and invasive breast cancer, but not for hip or
total fractures or total mortality, this time according to
whether participating women were using personal supple-
ments of either calcium or vitamin D at baseline. They
interpreted these data as providing evidence of benefit for
breast cancer and total cancer among women not taking
personal supplements. Chlebowski et al. [10] pointed out
the need for a cautious interpretation in these subgroup
analyses and described lack of support for a breast cancer
risk reduction from other WHI data sources.
Here, we use WHI data resources to examine these topics
further, with emphasis on the experience of women in the CT
who were not using calcium or vitamin D supplements at
baseline, as well as on the experience of the overall trial cohort.
We include comparative analyses from theWHI Observational
Study (OS), a prospective cohort study among 93,676 post-
menopausal women drawn from the same catchment areas, for
independent assessment of calcium and vitamin D health risks
and benefits in WHI populations. Since OS women may have
used these supplements for some years prior to WHI enroll-
ment, these data have potential to augment trial information on
the health effects of longer-term supplementation (e.g., 5 or
more years). In fact, there have been several observational
study reports of calcium supplementation in relation to car-
diovascular disease [11–15]. While most of these report null
or non-significant associations, the most recent of these
reported a noteworthy increase in MI, but not stroke, inci-
dence among the 3.6 % of an EPIC-Heidelberg cohort enroll-
ees who were identified as calcium supplement users [15].
These types of observational analyses can be difficult to
interpret since nutritional supplement users tend to have
quite different characteristics from non-users [e.g., 16], typ-
ically leaving uncertainty as to how completely confounding
has been controlled. Also, common reasons for taking nu-
tritional supplements include the belief that these prepara-
tions may prevent chronic diseases, such as cardiovascular
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disease, osteoporosis, and cancer [16, 17], raising the spec-
ter of “confounding by indication”, which may tend to offset
any “healthy supplement user” bias. Here, as in our earlier
WHI combined CT and OS analyses of postmenopausal
hormone therapy [18–23], our analyses allow for outcome-
specific residual confounding in the OS. In effect, these
combined CT and OS analyses allow an entirely separate
overall HR from the OS versus the CT, so that OS data are
used very conservatively to strengthen analysis of temporal
HR variation patterns. The OS data also permit some exam-
ination of disease outcome associations for calcium and
vitamin D supplementation separately.
Analyses presented here examine a range of clinical out-
comes including fractures, invasive cancers, cardiovascular
diseases, and total mortality. In each case, beyond overall
supplementation effects, temporal associations of the HR
with duration of supplementation, and the agreement of
patterns between clinical trial and observational study, are
examined. Urinary tract stone occurrence analyses in the
CT, by personal supplement use category, are also presented
to facilitate health benefit versus risk consideration.
Methods
Study populations and calcium and vitamin D
supplementation
A total of 36,282 postmenopausal women 50–79 years of age
were randomized at 40 clinical sites to 1,000 mg calcium plus
400 IU vitamin D3 daily, given in two equal doses, versus
placebo in the WHI CaD trial during 1994–99. Concurrent
calcium supplementation was permitted, as was vitamin D
supplementation up to 600 IU daily (later increased to
1,000 IU daily). Details of the study design [24] and baseline
characteristics [1, 2, 25] have been presented. All participating
women provided written informed consent.
No personal use of calcium or vitamin D supplements at
baseline was reported by 42.2 % (15,302) of trial enrollees,
whereas 43.5 % (15,796), 9.4 % (3,419), and 2.9 % (1,060)
reported use of calcium plus vitamin D, calcium only, and
vitamin D only, respectively, while baseline supplementation
information was not available for 1.9 % (705) of women. Both
single supplement and multivitamin/multimineral supple-
ments were included in assessing personal use.
The companion WHI prospective Observational Study
(OS) enrolled 93,676 postmenopausal women 50–79 years
of age from the same catchment population during 1994–98.
Baseline characteristics have been presented [26]. To align
with CT exclusionary criteria, we excluded 5,145 women
with a baseline history of breast cancer, 15,511 women with
no mammogram within 2 years prior to OS enrollment,
1,108 daily corticosteroid users, and 5,675 women who
reported urinary tract stones at baseline, leaving 68,719
OS women. Of these, 34.3 % (23,561) reported no baseline
supplementation with calcium or vitamin D, 49.9 %
(34,257) reported use of both calcium and vitamin D,
12.5 % (8,576) reported calcium only, and 3.4 % (2,325)
reported vitamin D only. Among the 42,833 baseline
calcium users, the 5th, 10th, 25th, 50th, 75th, 90th, and
95th percentiles for daily dosage (milligrams per day) were
57, 143, 200, 571, 1,000, 1,305, and 1,640, respectively. We
defined baseline calcium users in the OS as those taking
≥500 mg/day and excluded those consuming a lower dosage
from our analysis. This cutpoint gives a user group having
average daily dose similar to the 1,000 mg/day used in the
WHI trial. Similarly, the corresponding percentiles for vita-
min D (IU/day) were 125, 171, 400, 400, 400, 600, and 800
with 58 % of users reporting 400 IU/day. We defined vita-
min D users in the OS as those taking ≥400 IU/day and
excluded those taking a lower dosage from analysis. Fol-
lowing these exclusions, there were 15,476 calcium plus
vitamin D users, 5,941 calcium-only users, and 1,914 vita-
min D-only users at baseline in the OS which along with the
previously mentioned 23,561 non-users of either supple-
ment entails 46,892 OS women.
Data collection, follow-up, and outcome ascertainment
Clinical outcomes were self-reported semiannually in the
CT and annually in the OS [27]. Medical record documen-
tation of these reports was obtained and diagnoses were
confirmed at WHI clinical centers by physician adjudicators
who were blinded to clinical trial randomization assign-
ments. All clinical outcomes considered here, except certain
fractures in the OS, were locally confirmed in this manner.
Additionally, cases of coronary heart disease (CHD), stroke,
and death were further adjudicated by a central committee in
the CT, as were a fraction of such cases in the OS. Also,
locally confirmed cases of breast cancer, colorectal cancer,
and hip fracture in both the CT and OS were centrally
reviewed and classified at the WHI clinical coordinating
center. Fractures other than hip fractures were also adjudi-
cated in the CT, as was the case for a small fraction of other
fractures in the OS. Otherwise, self-report of fracture was
relied on in the OS.
Information on adherence to assigned study pills was
obtained semiannually in the CT through unused pill counts.
Dietary supplement data were collected in both the CT and
OS during in-person clinic visits. Women brought supplement
bottles to the baseline clinic visit and to annual visits thereafter
in the CT and to the baseline and 3-year clinic visit in the OS.
A standardized interviewer-administered four-page form was
used to collect information on single vitamin and mineral
supplements and on multivitamin/multimineral use. Staff
members directly transcribed the ingredients for each
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supplement and asked participants about the frequency (pills/
week) and duration (months and years) of use for each
supplement [28, 29].
The CaD trial ended as planned in March 2005 after
an average intervention period of 7.0 years. Follow-up
data from the OS are included here through 12/16/2004
to provide a comparable average follow-up period of
7.2 years. More recent health risk and benefit follow-up
data from the trial are currently being consolidated for a
separate presentation.
Standard procedures were used in the CT and OS to
collect data on age, race/ethnicity, reproductive/gynecologic
history, education, physical activity, medical history, family
or personal history of cancer or coronary heart disease,
diabetes mellitus, current health status, tobacco and alcohol
use, and self-administered food frequency questionnaire.
The WHI food frequency questionnaire (FFQ), in English
or Spanish, involved 122 foods or food groups, 19 adjust-
ment questions, 4 summary questions, and was designed to
assess typical intakes over the preceding 3 months [30].
Medication inventories were obtained at clinic visits, in the
same manner as dietary supplements.
Statistical analysis
Principal data analyses focus on the estimation of hazard
ratios corresponding to calcium and vitamin D supplemen-
tation, combined and separately, for each of the following
clinical outcomes: hip fracture, total fracture, invasive colo-
rectal cancer, invasive breast cancer, total invasive cancer
(excluding non-melanoma skin cancer), total mortality, MI,
CHD, total heart disease (CHD, revascularization, angina
pectoris, congestive heart failure) , stroke (combined ischemic
and hemorrhagic), and total cardiovascular disease (CVD)
(total heart disease, stroke, carotid artery disease, peripheral
vascular disease).
For each clinical outcome, the baseline hazard rate in the
Cox regression model is stratified on cohort (CT versus OS),
baseline age (5-year categories), and current use of post-
menopausal estrogens or estrogens plus progestin defined as
randomized to treatment if in the WHI hormone therapy
trials [24] and as current hormone therapy use at baseline
otherwise. Prior use of estrogens or estrogens plus proges-
tin, duration of any such prior use, and FFQ estimates of
usual calcium and vitamin D consumption were also includ-
ed as a modeled regression variables in the Cox model, in
both the CT and the OS. Time from WHI enrollment is the
“basic time variable” in these analyses. Hazard ratios were
calculated separately for <2, 2–5, and ≥5 years from initia-
tion of supplementation to assess the temporal relationship
between supplementation and any effects on clinical out-
come. In the CT, time from supplement initiation is defined
as time from randomization, whereas in the OS time from
initiation of supplement use is defined as the sum of dura-
tion of use at baseline plus time from OS enrollment.
Duration of use was defined as the longer of the two durations
for women using both calcium and vitamin D supplements at
baseline.
To further control confounding in the OS the hazard ratio
regression model included an outcome-specific list of poten-
tial baseline confounding factors as is shown in Supplemen-
tary Table 1. For each outcome, this list included a linear term
in age, an indicator of non-white ethnicity, body mass index
(BMI) categorized variables for 25–29.9, for 30–34.9, and for
≥35.0 along with a linear term in BMI, and indicator variables
for current or past cigarette smoking, in addition to other listed
outcome-specific variables.
Analyses for each clinical outcome category were carried
out using the entire CT enrollment, and also in the subsets of
women who were not taking personal calcium or vitamin D
supplements at baseline (“No personal supplements” subset)
or were doing so (“Personal supplements” subset), and HR
equality between these subsets was tested. For each analysis
hazard ratios (HRs) and estimated 95 % confidence intervals
(CIs) are presented according to years from supplement
initiation (<2, 2–5, and >5) as a time-varying covariate.
Significance levels (P values) are presented for a test of
trend across the three time from initiation categories, coded
as 0, 1, or 2, respectively. In addition, corresponding HR
estimates from combined trial and observational data sets
are given. These analyses allow for a residual confounding
in the OS, by including a product term in the regression
model between the OS versus CT indicator variable and the
CaD user indicator variable. This variable allows the HR for
CaD supplementation to differ by an overall multiplicative
factor in the OS compared to the CaD trial, so that the OS
data contribute to HR patterns with time from initiation but
not to the absolute HR assessments in these combined
analyses. With this modeling approach, overall HRs from
combined CT and OS analyses are identical to those from
the CT alone; but HR trend tests, which combine contribu-
tions from each cohort, may be strengthened by inclusion of
the OS data. HRs and 95 % CIs for the entire follow-up
period were calculated also, separately for the CT and OS.
Additional HR analyses in the CT censor the follow-up
for women 6 months after a change from baseline in sup-
plementation category, allowing the HRs to be interpreted in
terms of duration of supplement use among adherent wom-
en, with continuing adherence defined as taking 80 % or
more of assigned study medications in the preceding year.
These adherence-adjusted analyses were conducted with
and without inverse probability weighting in the Cox model,
with weighting by estimated adherence probability, and with
adherence probabilities estimated in a time-varying fashion
using logistic regression models that include the Supple-
mentary Table 1 variables.
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Analyses were also conducted separately according to de-
cade of baseline age and according to prior history of CVD.
Nominal 95 % CIs are presented for HR parameters, and
all P values presented are 2-sided.
Results
Table 1 shows number of cases for each clinical outcome
and age-adjusted incidence rates for both cohorts according
to randomization assignment in the CT and according to
baseline use of calcium and vitamin D supplements in the
OS. Incidence rates for most outcomes differed little be-
tween randomized groups in the CT.
Table 2 provides HR estimates for fracture, and death
according to years from CaD initiation, both for the CT as a
whole and for the trial subset not using personal calcium or
vitamin D at baseline; for the OS with outcome-specific
confounding control; and for the combined CT and OS, with
CT component including either the entire trial cohort or the
subset not using personal supplements.
In women not taking supplements at baseline, the HR for
hip fracture in the CT following 5 or more years of CaD
supplementation versus placebo was 0.62 (95 % CI, 0.38 to
1.00). In combined analyses of CT and OS data (with residual
confounding provision in the OS), the corresponding HR was
0.65 (95 % CI, 0.44 to 0.98) with evidence (P=0.02) of HR
trend with time from calcium and vitamin D initiation. Thus,
there was evidence for lower hip fracture rates following some
years of calcium plus vitamin D use in the subset of women
not taking personal calcium or vitamin D supplements. This
risk reduction was suggestive, but not clearly evident in the
trial cohort as a whole (HR 0.82; 95 % CI, 0.61 to 1.12), or in
combined trial and OS analyses. These combined overall CT
and OS analyses provide some evidence for hip fracture
benefit in the 5 or more years category (HR 0.78; 95 % CI,
0.59 to 1.03). Total fracture showed little evidence for associ-
ation with CaD supplementation, with HRs from the OS
tending to be larger than those from the CT.
To help interpret the hip fracture HRs, it can be noted that
the FFQ 5th, 25th, 50th, 75th, and 95th percentiles for
dietary calcium (milligram per day) were 291, 512, 738,
1,043, and 1,650, and for dietary vitamin D (IU/day), and
were 47, 96, 149, 221, and 397 in the CT. Corresponding
percentiles in the OS were 291, 571, 748, 1,074, and 1,693
for calcium, and 43, 93, 147, 225, and 407 for vitamin D,
very similar to those in the CT. It is evident that personal
supplement use of 500 mg/day or more calcium and 400 IU/
day or more of vitamin D contributes a substantial fraction
to the total consumption of these nutrients in study cohorts.
Table 2 also shows that total mortality was somewhat
reduced in the first 2 years from randomization among
women assigned to active treatment in the CT. This pattern
was not evident in later years of follow-up, in corresponding
OS analyses, or in combined CT and OS analyses.
Table 3 provides corresponding analyses for cardiovascular
diseases. There was little evidence for an adverse influence of
CaD supplementation on the risk for MI, CHD, total heart
disease, stroke, or total cardiovascular disease, from either the
CT or OS, or from their combined analysis. In fact, the OS
data alone suggest a reduction in total heart disease risk and
total cardiovascular disease risk among supplement users.
Table 4 presents corresponding analyses for invasive
cancer. Among women with no personal supplements at
baseline, there was some evidence for a reduction in breast
cancer risk (HR 0.80; 95 % CI, 0.66 to 0.96, P=0.02) and
total cancer risk (HR 0.88, 95 % CI, 0.78 to 0.98, P=0.03),
with little suggestion of HR time trend and with no support
from OS data. These patterns were similar in the trial cohort
as a whole, but far from significant.
Table 5 presents HRs from the OS for calcium-only and for
vitamin D-only supplementation. HRs for calcium plus vita-
min D are also repeated from earlier tables for comparative
purposes. As mentioned previously, these HRs are subject to
residual confounding and other biases, but comparative HRs
across supplement types presumably less so. Significant asso-
ciations were not found for hip fracture or for total fracture for
either supplement alone or combined. No associations of
calcium or vitamin D with incidence for the specific cancer
sites considered or for total invasive cancer were suggested by
these Table 5 analyses. A non-significant early elevation inMI
incidence with vitamin D is not precisely estimated and is not
apparent with the combination of calcium and vitamin D. HR
estimates were below one (P<0.05) for calcium alone in
relation to MI and CHD, and as previously mentioned, for
CaD in relation to total heart disease.
Data on adherence to assigned supplement category is
important for the interpretation of Table 5 analyses. Follow-
ing the baseline assessment, data on supplement use in the
OS was collected only in conjunction with a clinic visit
3 years later. Of the OS women using calcium plus vitamin
D at baseline, a substantial 80.9 % reported continued use
3 years later, with 10.9 % stopping use of both of these
supplements, 6.9 % moving to calcium-only, and 1.4 %
moving to vitamin D-only supplements. In contrast among
baseline calcium-only users, a remarkable 57.1 % had
moved to CaD preparations by 3 years later, with only
23.7 % still using calcium only, and 17.6 % had stopped
using either supplement. Similarly 56.5 % of baseline vitamin
D users had moved to CaD by 3 years later, with only 16.4 %
still using vitamin D only. Equally impressive, only 49.9 % of
baseline non-users of these supplements retained that status
3 years later, with 38.7 % becoming CaD users. It is evident
that the contrasts presented in Table 5 primarily pertain to CaD
use, and even then the non-user control group evidently
becomes quite contaminated over the follow-up period.
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Table 6 shows HR estimates from the CT using follow-up
data from each participating woman only during the period
of time that she remained adherent to her assigned active
CaD or placebo pills. Among adherent women, hip fracture
risk was lower in the active treatment group both in the
overall trial cohort (P=0.05), and in the subset of women
without personal supplements (P=0.04). The HR (95 % CI)
among adherent women not using personal supplements
was an impressive 0.24 (0.07, 0.84) following 5 or more
years of use among women not using personal supplements.
Themyocardial infarctionHR (95%CI) was a non-significant
1.18 (0.88, 1.59) among women not using personal calcium or
vitamin D. In contrast, breast and total invasive cancer risks
were reduced (both P=0.01) among women adherent to CaD
Table 1 Age-adjusted annualized incidence rates in the WHI CaD trial and observational study
CaD Trial Observational Study










Placebo CaD Placebo CaD
Number of women 18,106 18,176 7,584 7,718 23,561 15,476 5,941 1,914
Hip fracture
Cases 199 175 80 68 212 158 55 26
Age-adjusted incidence (%)b 0.20 0.17 0.20 0.16 0.14 0.15 0.13 0.18
Total fracture
Cases 2,158 2,102 870 872 3,172 2,344 834 290
Age-adjusted incidence (%)b 1.94 1.85 1.86 1.81 2.02 2.28 2.04 2.21
Myocardial infarction
Cases 390 411 167 193 433 210 77 40
Age-adjusted incidence (%)b 0.34 0.37 0.37 0.42 0.28 0.19 0.18 0.29
Coronary heart disease
Cases 475 499 211 229 545 252 95 50
Age-adjusted incidence (%)b 0.42 0.45 0.47 0.51 0.35 0.23 0.22 0.36
Total heart disease
Cases 1,363 1,405 642 621 1,602 762 328 132
Age-adjusted incidence (%)b 1.24 1.28 1.44 1.39 1.05 0.71 0.77 0.97
Stroke
Cases 377 362 162 184 471 253 91 38
Age-adjusted incidence (%)b 0.35 0.33 0.37 0.42 0.31 0.23 0.21 0.27
Total cardiovascular disease
Cases 1,810 1,832 813 848 2,187 1,069 440 181
Age-adjusted incidence (%)b 1.69 1.70 1.86 1.94 1.45 1.01 1.04 1.34
Colorectal cancer
Cases 154 168 77 66 174 88 35 9
Age-adjusted incidence (%)b 0.13 0.15 0.16 0.14 0.11 0.08 0.08 0.06
Breast cancer
Cases 546 528 249 202 665 517 210 60
Age-adjusted incidence (%)b 0.45 0.43 0.48 0.38 0.40 0.48 0.49 0.43
Total invasive cancer
Cases 1,411 1,366 617 553 1,701 1,187 474 153
Age-adjusted incidence (%)b 1.21 1.16 1.28 1.11 1.07 1.11 1.12 1.12
Death
Cases 807 744 338 331 1,240 674 266 119
Age-adjusted incidence (%)b 0.72 0.67 0.75 0.72 0.78 0.61 0.61 0.84
a No personal use of calcium or vitamin D at baseline
b Adjusted to the 5-year baseline age distribution in the CaD trial
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in these analyses. Analyses that incorporated inverse adher-
ence probability weights were similar with overall test P
values among women not using personal supplements of
0.02 for hip fracture, 0.98 for MI, 0.06 for invasive breast
cancer, and 0.01 for total invasive cancer.
For completeness, corresponding analyses were also car-
ried out for the complementary subset of 20,275 CT women
who reported taking personal supplements of calcium or
vitamin D, or both, at the time of WHI enrollment. Overall,
HRs (95 % CI) in this subset were as follows: hip fracture
0.90 (0.69,1.17), total fracture 0.95 (0.87,1.02), MI 0.97
(0.80,1.17), CHD 1.01 (0.85,1.20), total heart disease 1.04
(0.94,1.16), stroke 0.83 (0.67,1.01), total cardiovascular
disease 0.99 (0.90,1.08), colorectal cancer 1.32 (0.98,
1.79), breast cancer 1.09 (0.93,1.28), total invasive cancer
1.04 (0.94,1.15), and death 0.91 (0.79,1.04). None of these
HRs differ significantly from unity, though for some
outcomes, there is a significant HR difference between the
personal supplements and no personal supplements
subsets, including stroke (P=0.04), colorectal cancer
(P=0.04), breast cancer (P=0.01), and total invasive
cancer (P=0.03).
Among women who were adherent to study pills, the over-
all HRs (95 % CIs) in the personal supplements user subset
were as follows: hip fracture 0.85 (0.58,1.24), total fracture
0.97 (0.87,1.07), MI 0.96 (0.74,1.26), CHD 1.00 (0.79,1.28),
total heart disease 1.05 (0.91,1.21), stroke 0.81 (0.60,1.08),
total cardiovascular disease 1.01 (0.89,1.14), colorectal cancer
1.17 (0.78,1.73), breast cancer 1.04 (0.85,1.29), total invasive
cancer 1.02 (0.90,1.17), and death 0.91 (0.74,1.11). There was
significant adherent HR variation between the personal supple-
ments and no personal supplements subsets only for breast
cancer (P=0.03) and total invasive cancer (P=0.03) in these
adherence-adjusted analyses.
Table 2 Hazard ratios (bolded) and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and the
Observational Study according to years from supplement initiation: fractures and total deaths
Years since CaD initiation CaD trial Observational
study
Combined trial and OS
All participants No personal
supplementsa
All participants No personal
supplementsa
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Hip fracture
<2 0.75 0.44,1.26 1.12 0.52,2.42 1.41 0.44,4.57 0.81 0.49,1.31 1.15 0.58,2.30
2–5 1.01 0.73,1.40 1.00 0.61,1.65 1.22 0.71,2.10 1.03 0.77,1.39 1.04 0.68,1.57
>5 0.82 0.61,1.12 0.62 0.38,1.00 0.84 0.66,1.07 0.78 0.59,1.03 0.65 0.44,0.98
Trend testb 0.96 0.13 0.14 0.43 0.02
HR in OS/HR in trialc 1.09 0.78,1.54 1.28 0.82,1.98
Overall HRd 0.88 0.71, 1.08 0.86 0.62, 1.20 0.88 0.70, 1.11
Total fracture
<2 0.96 0.86,1.08 0.91 0.76,1.10 0.89 0.61,1.31 0.95 0.85,1.06 0.90 0.76,1.06
2–5 0.94 0.86,1.03 0.97 0.84,1.12 1.05 0.91,1.22 0.95 0.87,1.03 0.98 0.87,1.11
>5 0.98 0.88,1.09 1.03 0.87,1.22 1.08 1.01,1.14 0.98 0.90,1.08 1.02 0.90,1.16
Trend testb 0.83 0.35 0.42 0.53 0.21
HR in OS/HR in trialc 1.09 0.99,1.21 1.05 0.92,1.20
Overall HRd 0.96 0.90, 1.02 0.97 0.88, 1.07 1.07 1.01, 1.14
Death
<2 0.73 0.56,0.96 0.68 0.44,1.06 1.49 0.79,2.83 0.80 0.62,1.04 0.86 0.58,1.27
2–5 0.87 0.75,1.02 0.87 0.68,1.11 0.85 0.61,1.18 0.87 0.76,1.01 0.89 0.72,1.09
>5 1.01 0.87,1.18 1.12 0.89,1.40 0.95 0.85,1.06 0.99 0.86,1.13 1.04 0.86,1.26
Trend testb 0.03 0.03 0.71 0.09 0.17
HR in OS/HR in trialc 0.97 0.82,1.15 0.92 0.74,1.14
Overall HRd 0.91 0.83, 1.01 0.95 0.81, 1.11 0.95 0.85, 1.06
aWomen using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded
b Significance level (P value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively
c Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined
trial and cohort study analyses
d Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation
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Table 3 Hazard ratios (bolded) and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and
Observational Study according to years from supplement initiation: cardiovascular diseases
Years since CaD initiation CaD trial Observational
study
Combined trial and OS
All participants No personal
supplementsa
All participants No personal
supplementsa
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Myocardial infarction
<2 1.19 0.89,1.59 1.30 0.86,1.97 0.56 0.14,2.27 1.15 0.87,1.51 1.21 0.82,1.78
2–5 0.97 0.78,1.21 1.04 0.74,1.47 1.04 0.66,1.63 1.00 0.82,1.23 1.11 0.82,1.49
>5 1.01 0.80,1.29 1.06 0.74,1.50 0.89 0.73,1.08 1.00 0.80,1.24 1.05 0.78,1.41
Trend testb 0.46 0.49 0.94 0.49 0.54
HR in OS/HR in trialc 0.90 0.69,1.18 0.85 0.61,1.18
Overall HRd 1.03 0.90, 1.19 1.11 0.90, 1.37 0.90 0.75, 1.09
Coronary heart diseasee
<2 1.10 0.85,1.43 1.02 0.69,1.49 0.49 0.12,2.00 1.07 0.83,1.38 0.97 0.67,1.38
2–5 0.96 0.79,1.18 1.06 0.78,1.45 1.00 0.66,1.63 1.00 0.83,1.20 1.10 0.84,1.44
>5 1.05 0.85,1.30 1.02 0.75,1.40 0.88 0.74,1.05 1.03 0.85,1.25 1.02 0.78,1.33
Trend testb 0.87 0.97 0.88 0.93 0.93
HR in OS/HR in trialc 0.86 0.67,1.10 0.86 0.64,1.16
Overall HRd 1.03 0.90, 1.17 1.03 0.85, 1.25 0.88 0.74, 1.04
Total heart diseasef
<2 1.05 0.90,1.21 1.00 0.80,1.24 0.86 0.50,1.46 1.04 0.90,1.20 0.99 0.81,1.21
2–5 1.00 0.89,1.12 1.05 0.88,1.26 0.93 0.73,1.17 1.02 0.91,1.13 1.05 0.90,1.23
>5 1.04 0.91,1.19 0.98 0.81,1.20 0.87 0.79,0.97 1.02 0.91,1.15 0.99 0.84,1.16
Trend testb 0.96 0.91 0.83 0.88 0.91
HR in OS/HR in trialc 0.86 0.75,0.99 0.82 0.74,1.05
Overall HRd 1.02 0.95, 1.11 1.02 0.91, 1.14 0.87 0.79, 0.96
Strokeg
<2 0.82 0.60,1.12 1.11 0.73,1.68 0.47 0.12,1.89 0.78 0.58,1.05 1.00 0.68,1.46
2–5 1.06 0.84,1.34 1.17 0.83,1.65 0.91 0.57,1.44 1.03 0.84,1.27 1.16 0.87,1.55
>5 0.92 0.73,1.17 1.09 0.79,1.52 0.93 0.77,1.11 0.98 0.80,1.20 1.17 0.90,1.54
Trend testb 0.71 0.93 0.43 0.37 0.53
HR in OS/HR in trialc 0.96 0.75,1.23 0.81 0.60,1.09
Overall HRd 0.95 0.82, 1.10 1.12 0.90, 1.39 0.92 0.77, 1.09
Total cardiovascular diseaseh
<2 0.97 0.85,1.11 1.02 0.84,1.23 0.87 0.55,1.35 0.97 0.86,1.10 1.02 0.85,1.21
2–5 0.99 0.89,1.10 1.03 0.89,1.21 0.91 0.74,1.11 1.01 0.92,1.10 1.04 0.91,1.19
>5 1.05 0.93,1.18 1.02 0.86,1.21 0.86 0.79,0.94 1.02 0.93,1.13 1.01 0.88,1.16
Trend testb 0.37 0.97 0.84 0.42 0.93
HR in OS/HR in Trialc 0.85 0.75,0.96 0.85 0.73,0.99
Overall HRd 1.00 0.94, 1.07 1.03 0.93, 1.13 0.86 0.79, 0.94
aWomen using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded
b Significance level (P value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively
c Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined
trial and cohort study analyses
d Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation
e Non-fatal MI plus CHD death
f CHD plus revascularization, angina, and congestive heart failure
g Combined ischemic and hemorrhagic stroke
h Total heart disease plus stroke, carotid artery disease, and peripheral vascular disease
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Concerning urinary tract stones, as previously reported
[1, 7] 449 women (0.35 %) in the group randomized to CaD
and 381 women (0.30 %) in the placebo group developed
urinary tract stones during the trial intervention period,
leading to an HR (95 % CI) of 1.17 (1.02, 1.34). Among
adherent women, the HR (95 % CI) was 1.21 (0.98, 1.50).
These analyses were repeated here, separately for the no
personal supplements and personal supplements groups.
In the no personal supplements subset, the HR (95 % CI)
was 1.08 (0.88,1.32) based on 199 women developing urinary
tract stones in the active treatment group and 180 in the
placebo group. The corresponding HR (95 % CI) in the
personal supplements subset was 1.23 (1.01, 1.48) based on
239 and 197 women with stones in the active and placebo
groups. The HRs did not differ significantly (P=0.39) between
the two subsets. Among adherent women, the HR (95 % CI)
was 1.21 (0.87, 1.69) in the no personal supplements group
and 1.19 (0.89, 1.58) in the personal supplements group, with
no evidence (P=0.87) for difference between the HRs for
adherent women between the two subsets.
Subset analyses by age group or by prior CVD history
were generally similar to those for the overall cohorts for the
various outcomes considered above and are not shown.
Discussion
Our further analyses of WHI calcium and vitamin D trial
data, through the end of the intervention period, along with
corresponding and combined analyses using the WHI ob-
servational study, yields few clear clinical effects for daily
1,000 mg calcium plus 400 IU of vitamin D.
The strongest evidence for benefit is for hip fracture
where calcium and vitamin D supplementation yielded a
Table 4 Hazard ratios (bolded) and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and
Observational Study according to years from supplement initiation: invasive cancer
Years since CaD initiation CaD trial Observational
study
Combined trial and OS
All participants No personal
supplementsa
All participants No personal
supplementsa
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Colorectal cancer
<2 0.89 0.57,1.38 0.71 0.35,1.44 0.94 0.23,3.87 0.92 0.60,1.40 0.75 0.39,1.45
2–5 1.00 0.71,1.41 0.75 0.45,1.24 0.80 0.39,1.65 1.02 0.74,1.41 0.78 0.50,1.21
>5 1.30 0.88,1.92 0.99 0.56,1.77 0.83 0.60,1.14 1.23 0.87,1.74 0.90 0.56,1.45
Trend testb 0.19 0.44 0.96 0.26 0.57
HR in OS/HR in triald 0.69 0.45,1.07 0.94 0.55,1.59
Overall HRd 1.06 0.85, 1.32 0.81 0.58, 1.13 0.83 0.61, 1.12
Breast cancer
<2 1.00 0.79,1.27 0.98 0.68,1.42 0.90 0.44,1.83 0.97 0.78,1.22 0.88 0.64,1.22
2–5 0.98 0.82,1.18 0.75 0.56,1.00 1.05 0.78,1.41 0.95 0.81,1.12 0.75 0.59,0.95
>5 0.89 0.72,1.11 0.73 0.52,1.02 1.14 1.00,1.30 0.95 0.80,1.14 0.80 0.62,1.02
Trend testb 0.45 0.26 0.42 0.89 0.87
HR in OS/HR in trialc 1.18 0.96,1.45 1.42 1.09,1.84
Overall HRd 0.96 0.85, 1.08 0.80 0.66, 0.96 1.12 0.99, 1.28
Total invasive cancer
<2 0.96 0.83,1.12 0.96 0.76,1.22 0.87 0.56,1.36 0.95 0.82,1.09 0.91 0.74,1.12
2–5 0.94 0.84,1.06 0.82 0.69,0.98 0.99 0.82,1.20 0.94 0.85.1.05 0.84 0.73,0.97
>5 0.99 0.87,1.13 0.89 0.73,1.09 1.04 0.95,1.13 0.99 0.89,1.11 0.90 0.77,1.05
Trend testb 0.77 0.73 0.31 0.48 0.72
HR in OS/HR in triald 1.04 0.91,1.18 1.15 0.97,1.35
Overall HRd 0.96 0.89, 1.04 0.88 0.78, 0.98 1.03 0.95, 1.11
aWomen using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded
b Significance level (P value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively
c Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined
trial and cohort study analyses
d Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation
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noteworthy reduction after 5 years of treatment among
women not taking personal supplements, with HR (95 %
CI) of 0.62 (0.38, 1.00). It is important to note that hip
fracture was the sole primary outcome in the CaD trial,
reducing multiple testing limitations. Nevertheless, a cau-
tious interpretation is needed since this is a finding in the no
personal supplements subset, while the corresponding over-
all trial result (HR of 0.82, 95 % CI of 0.61 to 1.12) is not
significant. However, the likelihood of a hip fracture risk
reduction is enhanced by a significant (P=0.02) trend of
reducing HR with duration of supplementation in the no
personal supplements group and by nominally significant
Table 5 Hazard ratios (bolded) and 95 % confidence intervals for supplementation of calcium only and vitamin D only and for calcium and




Calcium only Vitamin D only CaD Calcium only Vitamin D only CaD
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Hip fracture Total fracture
<2 2.85 0.67,12.12 2.51 0.34,18.60 1.41 0.44,4.57 0.69 0.37,1.29 1.53 0.82,2.86 0.89 0.61,1.31
2–5 0.60 0.19,1.89 1.44 0.45,4.56 1.22 0.71,2.10 0.93 0.75,1.16 1.19 0.88,1.61 1.05 0.91,1.22
>5 0.82 0.58,1.15 1.17 0.73,1.86 0.84 0.66,1.07 1.00 0.91,1.09 1.02 0.88,1.18 1.08 1.01,1.14
Trend testa 0.49 0.48 0.14 0.26 0.15 0.42
Overall HRb 0.82 0.59, 1.14 1.23 0.80, 1.88 0.88 0.70,1.11 0.99 0.91,1.07 1.06 0.93,1.20 1.07 1.01,1.14
Myocardial infarction Coronary heart disease
<2 0.85 0.21,3.48 1.72 0.42,7.06 0.56 0.14,2.27 0.77 0.19,3.13 1.59 0.39,6.48 0.49 0.12,2.00
2–5 0.87 0.44,1.69 1.28 0.57,2.89 1.04 0.66,1.63 0.96 0.54,1.72 1.07 0.48,2.41 1.00 0.66,1.53
>5 0.71 0.53,0.97 0.99 0.67,1.47 0.89 0.73,1.08 0.74 0.56,0.97 1.02 0.72,1.45 0.88 0.74,1.05
Trend testa 0.60 0.38 0.94 0.53 0.61 0.88
Overall HRb 0.74 0.56, 0.97 1.06 0.75, 1.51 0.90 0.75,1.09 0.74 0.58,0.95 1.04 0.76,1.43 0.88 0.74,1.04
Total heart disease Stroke
<2 1.07 0.57,2.00 1.32 0.59,2.96 0.86 0.50,1.46 0.84 0.21,3.41 NAc 0.47 0.12,1.89
2–5 1.05 0.78,1.42 0.83 0.51,1.36 0.93 0.73,1.17 1.04 0.58,1.86 0.77 0.29,2.07 0.91 0.57,1.44
>5 0.95 0.82,1.10 0.97 0.78,1.20 0.87 0.79,0.97 0.81 0.62,1.07 0.82 0.55,1.23 0.93 0.77,1.11
Trend testa 0.47 0.82 0.83 0.47 0.45 0.28
Overall HRb 0.95 0.83, 1.08 0.96 0.79, 1.16 0.87 0.79,0.96 0.84 0.66,1.07 0.80 0.55,1.15 0.92 0.77,1.09
Total cardiovascular disease Colorectal cancer
<2 0.99 0.57,1.72 1.09 0.52,2.30 0.87 0.55,1.35 1.03 0.14,7.47 NAc 0.94 0.23,3.87
2–5 1.02 0.78,1.32 0.90 0.60,1.34 0.91 0.74,1.11 1.05 0.42,2.58 0.95 0.23,3.88 0.80 0.39,1.65
>5 0.89 0.79,1.01 0.92 0.76,1.10 0.86 0.79,0.94 1.01 0.66,1.55 0.64 0.28,1.46 0.83 0.60,1.14
Trend testa 0.31 0.81 0.84 0.96 0.91 0.96
Overall HRb 0.89 0.80,1.60 0.92 0.78,1.09 0.86 0.79,0.94 1.02 0.69,1.51 0.67 0.33,1.36 0.83 0.61,1.12
Breast cancer Total invasive cancer
<2 0.44 0.11,1.76 1.74 0.55,5.48 0.90 0.44,1.83 0.43 0.18,1.04 0.95 0.39,2.30 0.87 0.56,1.36
2–5 1.15 0.76,1.72 1.18 0.85,2.71 1.05 0.78,1.41 1.13 0.88,1.46 0.81 0.51,1.29 0.99 0.82,1.20
>5 1.18 0.98,1.42 1.11 0.62,1.23 1.14 1.00,1.30 1.12 0.99,1.26 1.05 0.87,1.28 1.04 0.95,1.13
Trend testa 0.30 0.07 0.42 0.18 0.40 0.31
Overall HRb 1.15 0.97,1.37 1.01 0.75,1.34 1.12 0.99.1.28 1.10 0.98,1.22 1.01 0.85,1.20 1.03 0.95,1.11
Death
<2 0.32 0.05,2.31 1.31 0.32,5.31 1.49 0.79,2.83
2–5 1.05 0.69,1.60 0.78 0.39,1.57 0.85 0.61,1.18
>5 0.93 0.80,1.09 1.09 0.87,1.35 0.95 0.85,1.06
Trend testa 0.81 0.60 0.71
Overall HRb 0.94 0.81,1.09 1.06 0.86,1.30 0.95 0.85,1.06
a Significance level (P value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively
b Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation
c NA—too few events for reliable HR calculation
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risk reductions over the entire follow-up period among
adherent women, both in the overall trial cohort and in the
no personal supplements subset (Table 6). For example,
these adherence-adjusted analyses yield an HR (95 % CI)
of 0.24 (0.07, 0.84) following 5 or more years of use among
women in the no personal supplements group, suggesting
that the public health implications of supplementation could
be substantial. Moreover, the biological plausibility of this
finding is also supported by higher (P<0.01) hip bone mineral
density (BMD) in the active treatment versus placebo group at
2, 5, and 8 years of follow-up [1]. Supplementary Figure 1
shows average hip, spine, and whole body BMD at baseline,
and at 2, 5, and 8 years later, by randomization group, overall,
and in the subset of women not using personal supplements,
Table 6 Hazard ratios (bolded) and 95 % confidence intervals for calcium and vitamin D supplementation in the WHI CaD trial according to
duration of supplementation among women adherent to their assigned study pills
Duration of CaD
supplementation
All participants No personal supplements All participants No personal supplements
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Hip fracture Total fracture
<2 0.62 0.33,1.15 0.88 0.32,2.43 0.95 0.83,1.08 0.87 0.70,1.06
2–5 0.83 0.50,1.37 0.66 0.28,1.52 0.90 0.79,1.03 0.91 0.73,1.13
>5 0.73 0.44,1.23 0.24 0.07,0.84 0.98 0.82,1.16 0.95 0.71,1.27
Trend testa 0.74 0.12 0.89 0.61
Overall HRb 0.73 0.54, 1.00 0.55 0.32, 0.97 0.94 0.86, 1.02 0.90 0.78, 1.03
Myocardial infarction Coronary heart disease
<2 1.23 0.90,1.69 1.37 0.86,2.18 1.21 0.90,1.62 1.14 0.74,1.76
2–5 1.07 0.78,1.49 1.35 0.81,2.26 1.01 0.74,1.36 1.26 0.78,2.01
>5 0.82 0.55,1.21 0.78 0.43,1.41 0.88 0.61,1.26 0.82 0.47,1.41
Trend testa 0.12 0.17 0.17 0.40
Overall HRb 1.06 0.87, 1.29 1.18 0.88, 1.59 1.04 0.87, 1.25 1.08 0.82, 1.42
Total heart disease Stroke
<2 1.06 0.89,1.25 1.05 0.82,1.34 0.81 0.57,1.14 1.01 0.63,1.64
2–5 1.01 0.85,1.19 1.00 0.77,1.31 1.19 0.85,1.67 1.73 0.99,3.01
>5 1.04 0.84,1.30 0.92 0.66,1.29 0.88 0.57,1.36 0.92 0.48,1.76
Trend testa 0.87 0.56 0.60 0.96
Overall HRb 1.03 0.93, 1.15 1.00 0.86, 1.18 0.96 0.78, 1.19 1.18 0.86, 1.62
Total cardiovascular disease Colorectal cancer
<2 0.98 0.85,1.14 1.04 0.84,1.29 0.91 0.56,1.47 0.73 0.34,1.60
2–5 1.04 0.89,1.20 1.07 0.84,1.34 1.01 0.62,1.66 0.92 0.44,1.93
>5 1.06 0.88,1.29 0.98 0.73,1.31 1.10 0.59,2.07 0.71 0.27,1.88
Trend testa 0.49 0.77 0.63 0.98
Overall HRb 1.02 0.93, 1.12 1.04 0.90, 1.19 0.99 0.73, 1.34 0.80 0.50, 1.27
Breast cancer Total invasive cancer
<2 0.96 0.73,1.27 0.90 0.58,1.39 0.97 0.82,1.14 0.94 0.71,1.23
2–5 0.85 0.66,1.10 0.60 0.39,0.92 0.86 0.74,1.02 0.70 0.53,0.92
>5 0.88 0.63,1.24 0.67 0.39,1.17 0.95 0.77,1.18 0.79 0.56,1.11
Trend testa 0.64 0.35 0.81 0.35
Overall HRb 0.90 0.76, 1.06 0.71 0.55, 0.93 0.92 0.83, 1.02 0.80 0.68, 0.95
Death
<2 0.78 0.57,1.08 0.69 0.41,1.16
2–5 0.81 0.63,1.04 0.82 0.54,1.26
>5 1.06 0.80,1.41 1.02 0.65,1.59
Trend testa 0.14 0.26
Overall HRb 0.88 0.75, 1.03 0.85 0.65, 1.11
a Significance level (P value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively
b Overall HR is the hazard ratio estimate when the HR is assumed not to depend on duration from supplementation
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with and without restriction to women adhering to assigned
study pills. A larger hip BMD in the intervention group is
evident overall, and among women not taking personal sup-
plements, and the difference is enhanced among adherent
women.
WHI data provide little support for an influence of calcium
and vitamin D supplementation on coronary heart disease risk
or cardiovascular disease risk more generally. Women ran-
domized to CaD do not have a significantly elevated risk of
MI, CHD, total heart disease, stroke or total cardiovascular
disease, either overall or in the subset not using supplements at
baseline. Furthermore, any suggestion of an early MI eleva-
tion is dampened by multiple testing considerations, since
none of the several cardiovascular disease categories consid-
ered were among the designated primary or secondary trial
outcome and any such suggestion was not enhanced by re-
striction to women who adhered to study medications. Also,
there was no suggested MI elevation in the OS. Moreover, in
the analyses of 754 women in the CaD trial who underwent
cardiac CT scans for assessment of coronary artery calcium
(CAC) scores at trial completion, no association between CaD
supplementation and CACwas observed, irrespective of base-
line intake of calcium and/or vitamin D [31]. However, given
concern about an elevation in MI with calcium use based on
other data sources [8], one should keep in mind the possibility
of an early MI elevation, but this hypothesis derives little
support from WHI data.
The analyses of CaD trial data suggest possible reductions
for invasive cancer with supplementation [3, 8]. Such HR
reductions are nominally significant for invasive breast cancer
(P=0.02) and for total invasive cancer (P=0.03) among wom-
en not using personal supplements, and these reductions per-
sisted following restriction to adherent women. However,
corresponding HR reductions were not significant for the trial
cohort as a whole. The fact that HRs for both breast cancer and
total cancer differed significantly between the personal sup-
plements and no personal supplements groups could reflect
HRs that are below unity at lower calcium and vitamin D
doses, and that flatten out at larger doses so that women using
personal supplements may have already achieved any cancer
risk reduction from supplementation, with little or no further
benefit from further supplementation. While this possibility is
intriguing, and potentially of public health importance, breast
and total cancer were not among the designated primary or
secondary outcomes for the CaD, so multiple testing consid-
erations, in conjunction with subset analysis and other [3]
considerations cause us to take a cautious interpretation of
these analyses. Hence, we regard the WHI data as merely
suggestive of invasive breast and total invasive cancer risk
reduction with available data.
Consistent with our previous report [7], we find no statis-
tically significant association between CaD supplementation
and death in the CaD trial overall or in the subgroup not using
personal supplements. There was no evidence in either the
CaD trial or the OS that long-term (≥5 years) CaD supple-
mentation reduced the risk of death. Specifically, the CaD
intervention did not affect death from coronary heart disease
where the hazard ratio was 0.99 (95 % CI, 0.71, 1.38) [7].
With this background, the only documented risk associated
with the randomized intervention in the CaD trial is a modest
elevation (HR of 1.17, 95 % CI from 1.02 to 1.34) in urinary
tract stone occurrence that did not differ significantly between
the personal supplements and no personal supplements subsets.
Observational data have several limitations in addressing
these types of research questions. For outcomes, such as hip
fractures and heart disease, where calcium and/or vitamin D
from foods or supplements may have developed a reputation as
potential disease preventatives, observational studies not only
need to control for standard confounding factors, but also for
factors related to confounding by indication since persons at
elevated risk for these diseases may self-select, or preferentially
be prescribed, these supplements. On the other hand, women
using dietary supplements are typically health conscious and
may have favorable risk factor profiles for some study diseases.
The extent to which confounding control efforts are adequate in
such challenging settings is usually unknown. In fact, we see
evidence of differing HRs for calcium plus vitamin D from the
CaD trial and the OS in Tables 2, 3, and 4 (i.e., HR in OS/HR in
CT differs from unity) for several outcomes including total
fracture, total heart disease, total cardiovascular disease, and
breast cancer. Even though some of these differences may arise
from differential adherence to supplementation, they reinforce
the need for a cautious approach to interpreting observational
associations of this type. Here, inclusion of the OS data did not
lead to any new findings but did contribute to evidence for a
hip fracture reduction, via our conservative combined clinical
trial and observational study data analyses.
Even though there is intense interest in the health effects of
supplementation using higher doses than 400 IU/day of vita-
min D, the WHI cohorts simply do not have enough women
using higher doses to attempt any meaningful analyses.
In summary, WHI clinical trial data are mostly null or
inconclusive concerning the health effects of calcium and
vitamin D supplementation. Compared to previous WHI
reports, the analyses presented here include a focus on whether
or not women were using personal supplements at the time of
WHI enrollment and a focus on temporal HR patterns across
the trial intervention period, leading to more compelling evi-
dence for a hip fracture risk reduction benefit that is somewhat
offset by a previously reported elevation in urinary tract stones.
Ultimate health benefits versus risks assessment for this inter-
vention could be favorably affected by a reduction in invasive
cancer, though evidence is only suggestive at present, while
data from other sources suggesting adverse cardiovascular
effects of calcium supplementation do not receive support from
WHI data. Decisions concerning supplementation with this
578 Osteoporos Int (2013) 24:567–580
combination may depend on many factors, including age and
sex, and importantly, risk for outcomes affected by CaD. Given
the widespread use of these supplements in the USA and
elsewhere, it will be important to continue to acquire data to
refine estimates of health benefits and risks among postmeno-
pausal women, and other societal groups, and to extend results
to other supplementation doses.
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